University College London (United Kingdom) Honorary Consultant in Sexual Health and HIV Medicine. Reader in Sexual Health and HIV

Transcription

1 Curriculum vitae PERSONAL INFORMATION Richard Gilson WORK EXPERIENCE December 1990 September 2014 October 2014 September 2018 October 2018 Present Senior Lecturer Honorary Consultant in Sexual Health and HIV Medicine Reader in Sexual Health and HIV Honorary consultant in sexual health and HIV medicine to Central and North West London NHS Foundation Trust Director of the Centre for Sexual Health and HIV Research (since 2010) Head of the Research Department of Infection and Population Health (since January 2013) Associate Professor Director, Centre for Clinical Research in Infection and Sexual Health Deputy Director, Institute for Global Health EDUCATION AND TRAINING October 1975 June 1981 May 1998 MB BChir Cambridge University (United Kingdom) Primary medical qualification Clinical course undertaken at Kings College Hospital Medical School MD Cambridge University (United Kingdom) MD thesis on interactions between hepatitis B and HIV ADDITIONAL INFORMATION Expertise I trained in genitourinary medicine and continue in clinical practice 1-2 days per week managing HIV and viral hepatitis outpatients and some general sexual health work. The Mortimer Market Centre at Central and North West London NHS Foundation Trust is the largest sexual health service in the country and the second largest HIV treatment centre with over 4000 patients. I have been responsible for the hepatitis clinic within the service since 1990, which provides treatment for both acute and chronic hepatitis B and C, including those with HIV-hepatitis co-infection, with over 500 patients in follow-up. The service is closely linked to the Centre for Sexual Health and HIV Research, of which I am Director (since 2010). The Centre is part of a larger Research Department of Infection and Population Health with over 80 staff based both at the Mortimer Market Centre and the Royal Free Hospital, of which I have been Head since The department has large programmes of work covering clinical and epidemiological studies in HIV, viral hepatitis and other sexually transmitted infections, and largely epidemiological studies in TB, flu and other community acquired infectious disease. Publications Selected recent publications: Miners, A., Llewellyn, C., King, C., Pollard, A., Roy, A., Gilson, R., Shahmanesh, M. (2018). Designing a brief behaviour change intervention to reduce sexually transmitted infections: a discrete choice 28/11/18 European Union, Page 1 / 5

2 experiment. International journal of STD & AIDS, Published on-line: doi: / Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, Speakman A, Antinori A, Balestra P, Bruun T, Gerstoft J, Nielsen L, Vassilenko A, Collins S, Rodger AJ. (2018). Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. AIDS and Behavior, 22 (5), doi: /s z Pufall, E. L., Kall, M., Shahmanesh, M., Nardone, A., Gilson, R., Delpech, V. on behalf of the Positive Voices study group. (2018). Sexualized drug use ('chemsex') and high-risk sexual behaviours in HIVpositive men who have sex with men. HIV Medicine. doi: /hiv Gourlay A, Fox J, Gafos M, Fidler S, Nwokolo N, Clarke A, Gilson R, Orkin C, Collins S, Porter K, Hart G (2017). A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. BMJ Open, 7 (8), e doi: /bmjopen Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R (2017). Hepatitis B serological markers and plasma DNA concentrations. AIDS, 31 (8), doi: /qad Long, L., Abraham, C., Paquette, R., Shahmanesh, M., Llewellyn, C., Townsend, A., Gilson, R. (2016). Brief interventions to prevent sexually transmitted infections suitable for in-service use: A systematic review. Preventive Medicine 91; Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutierrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kuemmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J. (2016). Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA 316 (2), doi: /jama Speakman A, Rodger A, Phillips AN, Gilson R, Johnson M, Fisher M, Wilkins E, Anderson J, O'Connell R, Lascar M, Aderogba K, Edwards S, McDonnell J, Perry N, Sherr L, Collins S, Hart G, Johnson AM, Miners A, Elford J, Geretti AM, Burman WJ, Lampe FC (2013). The Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study. Design, Methods and Participant Characteristics. PLoS One 8(10):e Haddow, L. J., Accoroni, A., Cartledge, J. D., Manji, H., Benn, P., Gilson, R. J. (2013). Routine detection and management of neurocognitive impairment in HIV-positive patients in a UK centre. Int J STD AIDS 24(3): doi: / Haddow, L. J., Floyd, S., Copas, A. J., Gilson, R. J. C. (2013). A Systematic Review of the Screening Accuracy of the HIV Dementia Scale and International HIV Dementia Scale. PLoS One 8(4), e61826 doi: /journal.pone Price, H., Gilson, R., Mercey, D., Copas, A., Parry, J., Nardone, A., Hart, G. (2013). Hepatitis C in men who have sex with men in London - a community survey. HIV Medicine, 14(9): doi: /hiv Rodger, A. J., Lodwick, R., Schecter, M. Rodger, A. J., Lodwick, R., Schechter, M, Deeks, S., Amin, J., Gilson, R., Paredes, R., Bakowska, E., Engsig, F., Phillips, A., for the INSIGHT SMART, ESPRIT Study Groups (2013). Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27(6): Lodi, S., Phillips, A., Fidler, S., Hawkins, D., Gilson, R., McLean, K., Fisher, M., Post, F., Johnson, A. M., Walker-Nthenda, L., Dunn, D., Porter, K., on behalf of the UK Register of HIV Seroconverters, (2013). Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure. PLoS One 8(9), e doi: /journal.pone Price, H., Gilson, R., Dunn, D., Pillay, D., Bani-Sadr, F., de Vries-Sluijs, T., Jain, M. K., Kuzushita, N., Mauss, S., Núñez, M., Nüesch, R., Peters, M., Reiberger, T., Stephan, C., Tan, L. (2013). Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. PLoS ONE 8(7) doi: /journal.pone Whitlock, G. G., Warwick, Z., Perry, N., Ottewill, M., Richardson, D., Fisher, M., Gilson, R. (2013). Why do men who have sex with men and who are at high risk of HIV infection, decline HIV testing? Int J STD AIDS 24(6), 503. doi: / Whitlock, G., Herbert, S., Copas, A., Gilson, R., Ainsworth, J. (2013). Avascular necrosis in HIVinfected patients: a case-control study. Int J STD AIDS 24(10): doi: / Winston, A., Jose, S., Gibbons, S., Back, D., Stohr, W., Post, F., Fisher, M., Gazzard, B., Nelson, M., Gilson, R., Orkin, C., Johnson, M., Palfreeman, A., Chadwick, D., Leen, C., Schwenk, A., Anderson, 28/11/18 European Union, Page 2 / 5

3 J., Gompels, M., Dunn, D., Khoo, S., Sabin, C., UK Collaborative HIV Cohort Study, (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother 68(6), doi: /jac/dkt029. Author URL Bansi, L., Gazzard, B., Post, F., Phillips, A., Johnson, M., Hill, T., Gilson, R., Leen, C., Walsh, J., Fisher, M., Sabin, C., UK Collaborative HIV Cohort Study, (2012). Biomarkers to Monitor Safety in People on ART and Risk of Mortality. J Acquir Immune Defic Syndr 60(1), doi: /qai.0b013e31824d2134. Barber, T. J., Harrison, L., Asboe, D., Williams, I., Kirk, S., Gilson, R., Bansi, L., Pillay, D., Dunn, D., UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees, (2012). Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother 67(4), doi: /jac/dkr569. Gompels, M., Dunn, D. T., Phillips, A., Dooley, D., De Burgh Thomas, A., Anderson, J., Post, F., Pillay, D., Gazzard, B., Hill, T., Johnson, M., Gilson, R., Bansi, L., Easterbrook, P., Fisher, M., Walsh, J., Orkin, C., Ainsworth, J., Leen, C., Sabin, C., UK Collaborative HIV Cohort (UK CHIC) Study (2012). Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy? J Infect Dis 205(4), doi: /infdis/jir380. Kober, C., Johnson, M., Fisher, M., Hill, T., Anderson, J., Bansi, L., Gompels, M., Palfreeman, A., Dunn, D., Gazzard, B., Gilson, R., Post, F., Phillips, A. N., Walsh, J., Orkin, C., Delpech, V., Ainsworth, J., Leen, C., Sabin, C. A., UK Collaborative HIV Cohort (CHIC) Study, (2012). Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/mu L in the UK. HIV Med 13(1), doi: /j x. Nebbia, G., Peppa, D., Schurich, A., Khanna, P., Singh, H. D., Cheng, Y., Rosenberg, W., Dusheiko, G., Gilson, R., ChinAleong, J., Kennedy, P., Maini, M. K. (2012). Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection. PLoS One 7(10), e doi: /journal.pone Price, H., Bansi, L., Sabin, C. A., Bhagani, S., Burroughs, A., Chadwick, D., Dunn, D., Fisher, M., Main, J., Nelson, M., Pillay, D., Rodger, A., Taylor, C., Gilson, R., UK Collaborative HIV Cohort Hepatitis Group, Steering Committee, (2012). Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study. PLoS One 7(11), e doi: /journal.pone Sultan, B. J., Fish, R., Carrick, G., Gilson, R., Robinson, A., Mercey, D., White, J., Benn, P. (2012). Is pooling of self-taken specimens an effective and acceptable method of testing for sexually transmitted infections in MSM? Sexually Transmitted Infections 88, A42-A43 doi: /sextrans c.98. Albert, M., Benito, J., Bhagani, S., Boesecke, C., Deterding, K., Dominguez, S., Fisher, M., Fontanet, A., Garcia, D., Gilson, R., Guiguet, M., Hoepelman, A. I. M., Horban, A., Katlama, C., Mallolas, J., Page, E., Peters, L., Pozniak, A., Prins, M., Puoti, M., Rauch, A., Rodger, A., Rockstroh, J. K., Soriano, V., Stephan, C., Thibault, V., Tural, C., Valantin, M. A., van de Laar, T., van der Meer, J., Vella, S., Vogel, M., de Wit, S., Autran, B., Clotet, B., Danta, M., Journiac, M., Matthews, G., Meyer-Olson, D., Nelson, M., Schmidt, R., Wedemeyer, H., and the European AIDS Treatment Network (NEAT) (2011). Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. AIDS 25(4), doi: /qad.0b013e b. Barber, T. J., Geretti, A. M., Anderson, J., Schwenk, A., Phillips, A. N., Bansi, L., Gilson, R., Hill, T., Walsh, J., Fisher, M., Johnson, M., Post, F., Easterbrook, P., Gazzard, B., Palfreeman, A., Orkin, C., Leen, C., Gompels, M., Dunn, D., Delpech, V., Pillay, D., Sabin, C. A., UK CHIC Study Steering Committee, (2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 16(6), doi: /imp1818. Projects Current research grants and projects: DISCOVER: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre- Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection (GS-US ). Funding: Gilead Sciences (contract research) - Local Principal Investigator Human papillomavirus infection: a randomised controlled trial of Imiquimod versus Podophyllotoxin, in 28/11/18 European Union, Page 3 / 5

4 combination with quadrivalent human papillomavirus vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac Trial). Funding: NIHR Health Technology Assessment Programme; Principal applicant and Chief Investigator ( ) Previous research grants and projects Sexual risk reduction interventions for patients attending sexual health clinics (Sante Project). Funding: NIHR Health Technology Assessment Programme; Principal applicant and Chief Investigator ( ) National longitudinal survey of healthcare needs and risk behaviours of HIV positive people. Funding; NIHR Centre for Public Health Research; Co-applicant (PI Dr Valerie Delpech, Public Health England) ( ) Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra in combination with Truvada for HIV post exposure prophylaxis (MiPEP Trial). Funding; Pfizer (investigator-initiated research award) Chief Investigator ( ). GS-US : A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). Funding: Gilead Sciences (contract research) - Local Principal Investigator (PI now transferred to Prof R Miller) GS-US : A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects. Funding: Gilead Sciences (contract research) - Local Principal Investigator (PI now transferred to Prof R Miller) Impact of hepatitis B co-infection in patients starting antiretroviral therapy. MRC Clinical Research Training Fellowship. Applicant H Price. First supervisor ( ) Epidemiology of HIV-associated immune reconstitution inflammatory syndrome in sub-saharan Africa. MRC Clinical Research Training Fellowship. Applicant: L Haddow. First supervisor (transfer of award to UCL mid-term) ( ) Effect of tenofovir/lamivudine on chronic hepatitis B virus infection in HIV co-infected patients enrolled in the DART Study. Funding; Gilead Sciences (investigator-initiated research award); Principal investigator ( ). UK CHIC extending the methodology to create a UCL cohort study. Funding: North Central London Research Consortium; Principal Investigator (grant ) Cryptogenic liver disease (CLD) in the HIV positive patient. Brian Gazzard Research Prize proposal; Applicant M Lascar. Principal supervisor; Prevalence and incidence of hepatitis C in male genitourinary medicine clinic attendees. Funding: North Central London Research Consortium and Roche (investigator-initiated research award); Principal Investigator ( ) Long-term follow-up of a database of HIV infected persons in seven major UK Centres (UK Collaborative HIV Cohort Study). Funding: MRC; Co-applicant and principal investigator for the Mortimer Market Centre (first applicant Prof.CA Sabin) for (I remain PI for the Mortimer Market Centre). The UK Register of HIV Seroconverters and Primary HIV Infection Study. Funding: MRC; Coapplicant (first applicant K Porter). MRC Grant, then MRC Clinical Trials Unit core funding. (continuing as local PI for the Mortimer Market Centre) Face-to-face versus self-interview methods in sexual health clinics. Funding: MRC; Co-applicant (first applicant J Richens); ( ) A multi-centre study of combination therapy for anogenital warts. Funding: Stiefel International Research (investigator-initiated research award); Principal investigator; ( ) Dynamics of the virus-specific immune response to hepatitis B virus infection. Funding: National Lottery Charities Board; Co-investigator; Principal investigator M Maini. ( ). Memberships Current roles: Chair of the British Association for Sexual Health and HIV Human Papillomavirus Special Interest Group since 2015 (and previously Scientific Secretary since 2002). I am the lead author on the latest update of the national guidelines on the management of ano-genital warts infection. Member of the HPV Sub-committee of the Joint Committee on Vaccination and Immunisation 28/11/18 European Union, Page 4 / 5

5 since 2013 charged with considering changes to the national HPV vaccination programme including reducing the number of doses, strategies to protect men who have sex with men, and the use of next generation polyvalent vaccines. Member of the Commission on Human Medicines, independent advisory group to the Medicines and Healthcare Products Regulatory Agency and the UK Ministers of Health (since December 2014) Previous roles: Ad-Hoc Group of Experts on Antiretroviral Medicinal Products. European Agency for the Evaluation of Medicinal Products 2001 British Association for Sexual Health and HIV; member of hepatitis guideline development groups Guidelines Committee of the Hepatitis Group of the British HIV Association (responsible for national hepatitis co-infection guidelines) since UCL Partners (Academic Health Sciences Collaboration) Research Advisory Board , and previously member of the UCL Health Sciences Deanery Research Strategy Committee, Consensus Panel on Acute Hepatitis C of the Network of European AIDS Treatment (NEAT - an EU funded Network of Excellence) 2010 Member of the Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO), Blood Donor Selection Steering Group ( ) this sub-committee of SaBTO was established to consider revision of the deferral criteria for blood and organ donation in relation to sexual behaviour. Other Relevant Information 28/11/18 European Union, Page 5 / 5